Article
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
The Journal of infectious diseases - 1 Mar 2010
Halvas Elias K, Wiegand Ann, Boltz Valerie F, Kearney Mary, Nissley Dwight, Wantman Michael, Hammer Scott M, Palmer Sarah, Vaida Florin, Coffin John M, Mellors John W
Abstract excerpt
BACKGROUND: The contribution of low frequency drug-resistant human immunodeficiency virus type 1 (HIV-1) variants to failure of antiretroviral therapy is not well defined in treatment-experienced patients. We sought to detect minor nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants at the initiation of multidrug efavirenz-containing therapy in both NNRTI-naive and NNRTI-experienced patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.